AU2021293911B2 - Compounds and methods for treating fungal infections - Google Patents

Compounds and methods for treating fungal infections Download PDF

Info

Publication number
AU2021293911B2
AU2021293911B2 AU2021293911A AU2021293911A AU2021293911B2 AU 2021293911 B2 AU2021293911 B2 AU 2021293911B2 AU 2021293911 A AU2021293911 A AU 2021293911A AU 2021293911 A AU2021293911 A AU 2021293911A AU 2021293911 B2 AU2021293911 B2 AU 2021293911B2
Authority
AU
Australia
Prior art keywords
spp
compound
pharmaceutically acceptable
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021293911A
Other languages
English (en)
Other versions
AU2021293911A1 (en
Inventor
Michael R. HODGES
Haran SCHLAMM
Karen Joy Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica International AG
Original Assignee
Basilea Pharmaceutica International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica International AG filed Critical Basilea Pharmaceutica International AG
Publication of AU2021293911A1 publication Critical patent/AU2021293911A1/en
Assigned to BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL reassignment BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL Request for Assignment Assignors: AMPLYX PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2021293911B2 publication Critical patent/AU2021293911B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021293911A 2020-06-17 2021-06-16 Compounds and methods for treating fungal infections Active AU2021293911B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040450P 2020-06-17 2020-06-17
US63/040,450 2020-06-17
PCT/US2021/037578 WO2021257670A1 (en) 2020-06-17 2021-06-16 Compounds and methods for treating fungal infections

Publications (2)

Publication Number Publication Date
AU2021293911A1 AU2021293911A1 (en) 2023-01-19
AU2021293911B2 true AU2021293911B2 (en) 2024-11-14

Family

ID=79268375

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021293911A Active AU2021293911B2 (en) 2020-06-17 2021-06-16 Compounds and methods for treating fungal infections

Country Status (12)

Country Link
US (1) US20230233586A1 (https=)
EP (1) EP4167998A4 (https=)
JP (1) JP2023530936A (https=)
KR (1) KR20230024375A (https=)
CN (1) CN115884775A (https=)
AU (1) AU2021293911B2 (https=)
BR (1) BR112022024988A2 (https=)
CA (1) CA3187268A1 (https=)
IL (1) IL299057A (https=)
MX (1) MX2022016179A (https=)
TW (1) TWI888580B (https=)
WO (1) WO2021257670A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010804A (es) 2020-03-04 2023-01-16 Amplyx Pharmaceuticals Inc Uso de compuestos en el tratamiento de infecciones fungicas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385169B (zh) * 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
US8513287B2 (en) * 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
EP2636409A1 (en) * 2010-11-05 2013-09-11 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
WO2020047510A1 (en) * 2018-08-31 2020-03-05 Amplyx Pharmaceuticals, Inc. Compounds and methods for treating fungal infections
US11819503B2 (en) * 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
MX2022010804A (es) * 2020-03-04 2023-01-16 Amplyx Pharmaceuticals Inc Uso de compuestos en el tratamiento de infecciones fungicas.

Also Published As

Publication number Publication date
CA3187268A1 (en) 2021-12-23
EP4167998A1 (en) 2023-04-26
JP2023530936A (ja) 2023-07-20
AU2021293911A1 (en) 2023-01-19
US20230233586A1 (en) 2023-07-27
KR20230024375A (ko) 2023-02-20
BR112022024988A2 (pt) 2022-12-27
WO2021257670A1 (en) 2021-12-23
MX2022016179A (es) 2023-04-20
EP4167998A4 (en) 2024-07-17
CN115884775A (zh) 2023-03-31
TW202214258A (zh) 2022-04-16
TWI888580B (zh) 2025-07-01
IL299057A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
US12521406B2 (en) Use of compounds in the treatment of fungal infections
JP7793681B2 (ja) 真菌感染症を処置するための化合物および方法
AU2021293911B2 (en) Compounds and methods for treating fungal infections
US12280032B2 (en) Methods and compositions for increasing the potency of antifungal agents
RU2824066C1 (ru) Соединения и способы для лечения грибковых инфекций
TW201919476A (zh) 在酸性ph值下具有經增強活性之抗真菌劑
HK40085944A (en) Compounds and methods for treating fungal infections
RU2805930C1 (ru) Использование соединений при лечении грибковых инфекций
US8987277B2 (en) Fungicide
HK40086224A (zh) 化合物在真菌感染的治疗中的用途
US20250302821A1 (en) Synergistic antifungal composition and method
TWI920017B (zh) 用於治療真菌感染之化合物及方法
KR20250090355A (ko) Iga 신병증 치료를 위한 엔도텔린 수용체 길항제 및 글루코코르티코이드의 조합
Riddell IV et al. Pharmacotherapy of micafungin: clinical review

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL

Free format text: FORMER APPLICANT(S): AMPLYX PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)